Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

65 results about "Carbamoyl phosphate synthetase" patented technology

Carbamoyl phosphate synthetase catalyzes the ATP-dependent synthesis of carbamoyl phosphate from glutamine (EC 6.3.5.5) or ammonia (EC 6.3.4.16) and bicarbonate. This enzyme catalyzes the reaction of ATP and bicarbonate to produce carboxy phosphate and ADP. Carboxy phosphate reacts with ammonia to give carbamic acid. In turn, carbamic acid reacts with a second ATP to give carbamoyl phosphate plus ADP.

Function and application of thymidylate synthetase CAD (carbamoyl-phosphate synthetase II, aspartate transcarbamylase and dihydroorotase) gene in treating fatty liver and type-II diabetes mellitus

ActiveCN104069511AImprove fatty liverImprove type 2 diabetesPeptide/protein ingredientsMetabolism disorderIntraperitoneal routeStaining
The invention discloses a function and application of thymidylate synthetase CAD (carbamoyl-phosphate synthetase II, aspartate transcarbamylase and dihydroorotase) genes in treating fatty liver and type-II diabetes mellitus, and belongs to the field of gene functions and application. Functions of CAD genes are studied by a high-fat diet (HFD) induced model, and results discover that the levels of body weight and fasting blood-glucose of a CAD gene knock-out mouse in an HFD group are higher than those of a WT (Wild Type) mouse in a control group; glucose tolerance tests by intraperitoneal injection discover that the tolerance of the CAD gene knock-out mouse on glucose is remarkably weakened; the integral liver appearance, liver weight, liver/weight ratio and lipid component pathological staining result of the mouse indicate that the fatty liver disease of the CAD knock-out mouse in the HFD group is remarkably severe, the lipid accumulation is remarkably increased, and these results indicate that CAD gene knock-out can remarkably deteriorate fatty liver and type-II diabetes mellitus. Regarding the effects of CAD, the CAD can be used for preparing medicaments for preventing, relieving and/or treating fatty liver and/or type-II diabetes mellitus.
Owner:武汉惠康基因科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products